Request Trial
shutterstock_515105209_wanpatsorn
Wanpatsorn / Shutterstock.com
4 November 2019Rory O'Neill

Latham and Watkins promote three

Latham and Watkins has unveiled two new IP partners and one counsel as part of its annual appointments and promotions.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Asia
Takeda’s China IP head: What pharma is still getting wrong
27 May 2026   China’s IP system is undergoing real change. Takeda’s IP head for the region explains what that looks like on the ground and why the old playbook no longer cuts it.
Careers
Boehringer Ingelheim adds ex-Teva executive to patent team
27 May 2026   A senior pharmaceutical lawyer, with experience across private practice and Big Pharma, joins the company after a decade-long tenure at Teva.
Americas
AI, anxiety, and antibodies: The issues dominating life sciences
26 May 2026   Two days of discussions at LSPN North America revealed an industry grappling with narrower patent claims, global strategy changes, AI disruption and tougher dealmaking conditions.


Editor's picks

Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026

Editor's picks

Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026
Americas
From the courtroom: Hikma v Amarin SCOTUS oral arguments
30 April 2026
Americas
Penile implant maker’s $17m trade secret award unravels
20 April 2026
Biotechnology
Closing the women's health gap offers ‘benefits for all’
7 April 2026
Europe
European patent offices raise fees
2 April 2026
Americas
Argentina’s patent reset: Why pharma can no longer ignore Latin America's second-largest market
1 April 2026

More features

Takeda’s China IP head: What pharma is still getting wrong
Boehringer Ingelheim adds ex-Teva executive to patent team
AI, anxiety, and antibodies: The issues dominating life sciences
UPC judge: ‘Expectations of you as a woman are the challenge’
How should in-house teams adopt AI? ‘Carefully’, says secrets expert
Lupin scores another win in kidney drug dispute
Battle over inhaler shape ends badly for Boehringer
Chinese medtech company fined by UPC over injunction breaches